Table 1.
Potency of PE in thoracic aortas from Gla+/0 and Gla−/0 mice in the presence of COX inhibitors with and without endothelium
|
−log EC50, M |
||||
|---|---|---|---|---|
|
+Endo |
−Endo
|
|||
| Gla+/0 | Gla−/0 | Gla+/0 | Gla−/0 | |
| Control | 6.92±0.06(8) | 6.70±0.06† (10) | 7.75±0.05 (5) | 7.80±0.09 (7) |
| Indomethacin | 6.74±0.07*(10) | 6.54±0.09 (10) | 7.90±0.04 (5) | 7.84±0.07 (7) |
| Valeryl salicylate | 6.98±0.05 (8) | 6.64±0.11† (8) | 7.68±0.06 (5) | 7.54±0.09 (7) |
| NS-398 | 6.62±0.04*(10) | 6.35±0.11†‡ (10) | 7.87±0.03 (5) | 7.82±0.06 (7) |
Values are means ± SE for number of animals in parentheses. +Endo, endothelium intact; −Endo, endothelium denuded; Gla+/0 and Gla−/0, α-galactosidase A (Gla) wild-type and Gla-knockout mice, respectively.
*
P < 0.05 vs. Gla+/0 control (by 1-way ANOVA with Newman-Keuls multiple comparison post hoc test).
†
P < 0.05 vs. Gla+/0 in respective treatment group (by unpaired t-test).
‡
P < 0.05 vs. Gla−/0 control (by 1-way ANOVA with Newman-Keuls multiple comparison post hoc test).